Melvin Capital Management’s Labcorp LH Stock Holding History

Melvin Capital Management’s Portfolio LH Stock Details LH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-232,800	Closed	-$62.8M	–	66
2021 Q4	$62.8M	Hold	232,800	–	–	0.31%	63
2021 Q3	$56.3M	Sell	232,800 -698,400	-75%	-$176M	0.29%	75
2021 Q2	$221M	Buy	+931,200	New	+$212M	1.27%	34
2020 Q1	–	Sell	-465,600	Closed	-$67.7M	–	115
2019 Q4	$67.7M	Buy	+465,600	New	+$67.2M	0.56%	52

Other funds holding LH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Melvin Capital Management's LH Position: Q2 2022 in Review

Melvin Capital Management sold out of Labcorp (LH) in Q2 2022, closing a stake of 899,416 shares — an estimated $204M sold.

Melvin Capital Management first reported a position in LH in Q2 2019 and held it in 12 quarters. The position peaked at $621M in Q4 2021. 967 funds tracked by Wall St. Rank hold LH as of Q2 2022.

Melvin Capital Management reported no remaining Labcorp position as of Q2 2022 after selling out during the quarter.
Melvin Capital Management sold 899,416 Labcorp shares in Q2 2022, an estimated $204M.
Melvin Capital Management first reported a position in Labcorp in Q2 2019 and held it in 12 quarters.
Melvin Capital Management's Labcorp position peaked at $621M in Q4 2021.
967 funds tracked by Wall St. Rank held Labcorp as of Q2 2022.

Based on Melvin Capital Management's 13F filing for Q2 2022.